JAK2 MUTATION, TNF-Α AND IL 6 PREDICT RESPONSE TO JAK INHIBITOR IN RHEUMATOID ARTHRITIS PATIENTS

被引：0
|
作者：
Hussein, Y. Adel Abdelsalam [1 ]
Sadeq, Y. [2 ]
机构：
[1] Mansoura Univ Hosp, Rheumatol, Mansoura, Egypt
[2] Mansoura Univ Hosp, Clin Pathol, Mansoura, Egypt
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Rheumatoid arthritis; Prognostic factors;
D O I：
10.1136/annrheumdis-2023-eular.840
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0358
引用
收藏
页码：429 / 430
页数：2
相关论文
共 50 条
  • [1] JAK2 MUTATION MAY PREDICT RESPONSE AND GUIDE FIRST LINE TREATMENT IN RHEUMATOID ARTHRITIS
    Hussein, Y. Adel Abdelsalam
    Sadeq, Y.
    Sabry, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 582 - 583
  • [2] JAK2 mutation may predict response and guide first line treatment in rheumatoid arthritis
    Adel, Yasmin
    Sabry, Mohamed
    El-Sabbagh, Amr Mohamed
    Sadeq, Yousra
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2021, 33 (01):
  • [3] JAK2 mutation may predict response and guide first line treatment in rheumatoid arthritis
    Yasmin Adel
    Mohamed Sabry
    Amr Mohamed El-Sabbagh
    Yousra Sadeq
    The Egyptian Journal of Internal Medicine, 2021, 33
  • [4] Plasma and JAK2 mutation Response
    Albitar, Maher
    Ma, Wanlong
    Kantarjian, Hagop
    Giles, Francis
    BLOOD, 2009, 114 (01) : 224 - 224
  • [5] BARICITINIB Tyrosine-Protein Kinase JAK1/JAK2 Inhibitor Treatment of Rheumatoid Arthritis
    Gras, Jordi
    DRUGS OF THE FUTURE, 2013, 38 (09) : 611 - 617
  • [6] How Fast Do JAK-inhibitors, TNF- inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the "JAK-pot" Study)
    Courvoisier, Delphine Sophie
    Mrad, Yacine
    Mongin, Denis
    Aymon, Romain
    Caporali, Roberto
    Choquette, Denis
    Codreanu, Catalin
    Coupal, Louis
    Huschek, Doreen
    Hyrich, Kimme
    Iannone, Florenzo
    Kvien, Tore K.
    Mustak, Monika
    Nordstrom, Dan
    Trokovic, Nina
    Otero-Varela, Lucia
    Pavelka, Karel
    Suarez, Manuel Enrique Pombo
    Provan, Sella A.
    Rodrigues, Ana Maria
    Rotar, Ziga
    Sidiropoulos, Prodromos
    Strangfeld, Anja
    Zavada, Jakub
    Zhao, Sizheng
    Finckh, Axel
    Lauper, Kim
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1014 - 1017
  • [7] BARICITINIB, AN ORAL JANUS KINASE (JAK) 1/JAK2 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ( RA) AND AN INADEQUATE RESPONSE TO TNF INHIBITORS: RESULTS OF THE PHASE 3 RA-BEACON STUDY
    Genovese, M. C.
    Kremer, J.
    Zamani, O.
    Ludivico, C.
    Krogulec, M.
    Xie, L.
    Beattie, S.
    Koch, A. E.
    Cardillo, T.
    Rooney, T.
    Macias, W.
    Schlichting, D.
    Smolen, J. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 75 - 76
  • [8] The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
    Choy, E. H. S.
    Miceli-Richard, C.
    Gonzalez-Gay, M. A.
    Sinigaglia, L.
    Schlichting, D. E.
    Meszaros, G.
    de la Torre, I.
    Schulze-Koops, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : 694 - 704
  • [9] Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis
    Wu, Ting-Shuan
    Chen, Yi-Ming
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1883 - 1884
  • [10] Novel Regulation of TNF-α-Induced-IL-18 Bioactivity in Rheumatoid Arthritis Synovial Fibroblasts by Reducing Caspase-1 Via JAK2 Inhibition
    Marotte, Hubert
    Fedorova, Tatiana
    Pinney, Adam J.
    Lewis, Benjamin
    Koch, Alisa E.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1008 - S1008
12345